(Q37491763)

20 August 2017

1 reference

title

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease (English)

1 reference

20 August 2017

1 reference

cardiovascular disease

1 reference

Richard Kones

1

1 reference

20 August 2017

21 May 2009

1 reference

Therapeutic advances in cardiovascular disease

20 August 2017

1 reference

20 August 2017

3

1 reference

20 August 2017

4

1 reference

20 August 2017

309-315

1 reference

Standards of medical care in diabetes--2009.

20 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Further improvements in CHD risk prediction for women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Expanding the orbit of primary prevention--moving beyond JUPITER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

What does minor elevation of C-reactive protein signify?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Noncholesterol-Lowering Effects of Statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Isoprenoid metabolism and the pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Multiple biomarkers for the prediction of first major cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

Cardiovascular risk assessment--where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

C-reactive protein: the pawn has been promoted to queen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709337056

21 January 2018

Identifiers

DOI

10.1177/1753944709337056

1 reference

20 August 2017

1 reference

PubMed ID

19460829